In Diabetes, experts at Lund University unveiled a drug candidate able to raise insulin secretion in type 2 diabetes (T2D).
Their research centered on a specific microRNA known as miR-200c. The findings shows that the levels of miR-200c varys between people with type 2 diabetes and without.
“Here we report increased expression of miR-200c in islets from T2D as compared with nondiabetic (ND) donors and display results showing reduced glucose-stimulated insulin secretion in EndoC-βH1 cells overexpressing miR-200c,” the authors explained in their findings.
“In this study we have identified miR-200c as an miRNA differentially upregulated in human islets from T2D donors. Moreover, we identified ETV5 as an interesting novel target of miR-200c in human islets, together with the identification of previous targets validated in rodent models such as JAZF1.”
“Our data reveal a vital role of the miR-200c–ETV5 axis in β-cell dysfunction and pathophysiology of T2D,” the authors determined.
